Bempedoic acid (NEXLETOL in the USA; Nilemdo in the EU), and an FDC of bempedoic acid/ezetimibe (NEXLIZET in the USA; Nustendi in the EU), are the first of this drug type to be approved for CV risk reduction in statin-intolerant adults who are at high risk for, or who have, ...
Review article Lipoprotein(a) 1.6 Bempedoic acid Bempedoic acid is an oral lipid-modifying agent that inhibits adenosine triphosphate citrate lyase, upstream from HMG-CoA reductase, to decrease cholesterol biosynthesis in the liver, upregulate the LDL receptor, and increase clearance of LDL. Although ...
But, if patients are intolerant to statins then adding bempedoic acid to reduce LDL levels should be considered. Funding No funding was received for this manuscript. Author contributions Dr. Yarrarapu and Dr. Goyal conceived the notion of composing this review article, while Dr. Panchal and Dr....
现代药物与临床 Drugs & Clinic 第 30 卷第 11 期 2015 年 11 月·1417· • 未来药物 • 新型降脂药物 bempedoic acid 褚小琴 1,闫少杰 2,张远 2,李树军 2,王平保 2* 1. 天津医科大学 研究生院,天津 300070 2. 天津药物研究院 化学制药部,天津 300193 摘要:血脂异常是心血管疾病的一个高危因素,...
This 32-country randomized clinical trial assesses the effects of bempedoic acid on cardiovascular outcomes in statin-intolerant patients receiving
This study aimed to systematically review and conduct a meta-analysis of randomized controlled trials investigating the efficacy and safety of bempedoic acid in statin-intolerant patients with hyperlipidemia and to provide conclusions and recommendations acco...
Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor Bempedoic acid (ETC-1002) is a new agent that reduces cholesterol synthesis through inhibition of adenosine triphosphate citrate lyase (ACL), an enzyme ups... NK Zagelbaum,S Yandrapalli,C Nabors,... - 《Cardiology in Review》 被引量:...
Therefore, the aim of this article is to conduct a comprehensive evaluation of the impact of bempedoic acid on the incidence of cardiovascular events. Methods: A systematic review and meta-analysis of randomized controlled trials pertaining to bempedoic acid was carried out. We conduct...
Bempedoic acid (BA) is an oral adenosine triphosphate citrate lyase inhibitor that was shown to reduce the risk of major adverse cardiovascular events (MACE) in patients unable to take statins due to statin-associated side effects (SASEs) who are at high cardiovascular risk or have established at...
We review all the phase II and III studies carried out with bempedoic acid at the dose of 180 mg, alone or in combination with different lipid-lowering drugs and in different subgroups of patients that unequivocally show the efficacy and safety of the drug. We point out some of the potentia...